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ESSAY
Quality of Life in HIV Clinical Trials:
Why Sexual Health Must Not Be Ignored
Olivier Koole, Christiana Noestlinger, Robert Colebunders*
Sexual Health and Antiretroviral
Therapy
Currently more than 20 antiretrovirals
are commercially available for treat-
ment of HIV infection [1]. Using them
in combination therapy, we are able to
treat HIV-infected patients with highly
potent regimens and suppress the virus
below detectable levels. Correct adher-
ence to these regimens is important to
ensure that the viral load will remain
undetectable and that the disease does
not progress. Moreover, even if adher-
ence is not perfect and the virus
becomes resistant to a ﬁrst-line regi-
men, there are other treatment options
to suppress the virus again to undetect-
able levels.
Given the choice of several different
potent antiretroviral regimens, doctors
and patients will tend to prefer those
regimens that are easy to take and that
have limited short-term and long-term
side effects.
One potential side effect of antiretro-
viral treatment that has received very
little scientiﬁc attention so far is sexual
dysfunction. Sexual dysfunction is de-
ﬁned as difﬁculty during any stage of
the sexual act, including desire, arousal,
orgasm, and resolution, that prevents the
individual or couple from enjoying sexual
activity [2], and, according to DSM-IV
(the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition) criteria,
causing ‘‘marked level of distress or
interpersonal difﬁculty’’ [3]. Sexual dys-
function disorders are generally classiﬁed
into four categories: sexual desire disor-
ders, sexual arousal disorders, orgasm
disorders, and sexual pain disorders [2,3].
Most data relating to the association
between antiretroviral therapy and sexual
dysfunction are based on cross-sectional
studies or case series, and have emerged
from industrialised countries [4–12].
Some studies have suggested that antire-
trovirals, in particular certain protease
inhibitors, may cause sexual problems or
dysfunction [4–10]; however, other stud-
ies have not conﬁrmed this observation
[11,12].
Furthermore, sexual dysfunctions in
people infected with HIV may be caused
by many different factors. Both organic
and psychological factors have been
identiﬁed, including coping with HIV,
pre-existing sexual dysfunctions, sex hor-
mone abnormalities, neuropathy from
HIV itself (or related treatment for HIV-
caused illnesses), and other iatrogenic
causes [13].
Sexual dysfunctions are conceptualised
as one component of sexual health, which
is an essential element of overall health-
related quality of life (HRQOL). While it
may include a variety of diverse issues,
comprehensive deﬁnitions such as the
World Health Organization’s (WHO)
working deﬁnition deﬁne sexual health
as a state of physical, emotional, mental,
and social well-being, and not merely
the absence of disease, dysfunction, or
inﬁrmity. Sexual health encompasses the
possibility of having pleasurable and safe
sexual experiences [14]. The essence of
such lengthy deﬁnitions has been sum-
marised in one single statement as ‘‘the
enjoyment of sexual activity of one’s
choice, without causing or suffering phys-
Table 1. Overview of the Most Commonly Used Questionnaires in Clinical HIV Trials
Questionnaire Description
MOS-HIV questionnaire The 35-item MOS-HIV assesses ten domains of functioning and well-being, includ-
ing physical function, social and role function (work), cognitive function, pain,
mental health, energy, distress about health, quality of life, and overall health.
EuroQoL(EQ-5D) The EuroQoL (EQ-5D) describes states of health in five dimensions: mobility, self
care, usual activities, pain or discomfort, and anxiety or depression.
SF-36 The SF-36 includes one multi-item scale that assesses eight health concepts: lim-
itations in physical activities because of health problems, limitations in social ac-
tivities because of physical or emotional problems, limitations in usual role activ-
ities because of physical health problems, bodily pain, general mental health
(psychological distress and well-being), limitations in usual role activities because
of emotional problems, vitality (energy and fatigue), and general health percep-
tions.
WHOQOL-HIV The WHOQOL-HIV is a 125 item questionnaire on the same six dimensions as the
WHOQOL-100 questionnaire [20]:
physical health, psychological health, level of independence, social relations, en-
vironment, and spirituality/religion/personal beliefs. It includes five questions on
sexual health.
doi:10.1371/journal.pctr.0020008.t001
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ical or mental harm’’ [15]. The latter may
pose a particular challenge for people
living with HIV/AIDS (PLHA) due to HIV-
related stigma and the psychological
impact of HIV. As such, sexual health is
clearly linked with perceived overall qual-
ity of life.
Ideally, we should assess sexual health,
including sexual functioning, during
randomised clinical trials (RCTs) compar-
ing different antiretroviral regimens,
early versus late initiation of antiretrovi-
ral therapy, and treatment interruption
studies. This could be done by including
questions on sexual health in quality of
life questionnaires that are administered
during such clinical trials. However,
quality of life questionnaires that are
currently used in HIV clinical trials
usually do not include such questions.
Questionnaires Used in HIV
Clinical Trials
The quality of life questionnaires used
most widely in HIV clinical trials are the
MOS-HIV questionnaire [16] and to a
lesser extent the EuroQoL (EQ-5D) ques-
tionnaire [17] (Table 1).
The MOS-HIV is a brief (generally
taking less than ten minutes) comprehen-
sive health status measure based on
questions from the Medical Outcomes
Study, a large multi-site study of the
effects of different ways of delivering
medical care [21]. The MOS-HIV was
one of the ﬁrst disease-targeted quality
of life questionnaires available for PLHA,
and is widely used in clinical trials and
other research and evaluation studies.
The EQ-5D is a simple instrument assess-
ing only ﬁve dimensions of health. In both
questionnaires, MOS-HIV and EQ-5D,
there are no questions concerning sexual
health.
The most widely used health status
instrument in other domains is the SF-
36 [18] (which is also derived from the
Medical Outcomes Study). Other ques-
tionnaires assessing quality of life are the
quality of well-being scale (QWBS) [22]
and the Health Utilities Index (HUI)
questionnaire [23]. None of these ques-
tionnaires include sexual health ques-
tions.
The only questionnaire that does in-
clude sexual health questions is the WHO
QOL-HIV questionnaire [19]. This ques-
tionnaire is based on the WHOQOL-100
questionnaire [20]. Among 120 questions
included in this questionnaire, ﬁve ques-
tions address sexual health and one
speciﬁcally sexual dysfunction: ‘‘Are you
bothered by any difﬁculties in your sex
life?’’ (Box 1).
One hundred and twenty questions
pose quite a heavy burden on both the
interviewer and the patient/interviewee.
In addition, given the sensitive character
of questions on sexual health, one may
anticipate that these questions would be
the ﬁrst ones to be omitted from a
questionnaire during an assessment.
Why Should Sexual Health Be
Assessed During HIV Clinical
Trials?
The importance of sex in most people’s
lives is illustrated by the fact that there is
a growing market for drugs that increase
sexual pleasure. The pharmaceutical
industry has recently discovered this
market, which has resulted in the devel-
opment of popular erectile dysfunction
medications such as sildenaﬁl (Viagra),
tadalaﬁl (Cialis), and vardenaﬁl (Levitra)
(Figure 1). Evidence from studies in the
United Kingdom and United States [24–
26] show that these drugs are also
commonly used among HIV-infected
people, particularly by men who have
sex with men (MSM).
A recent study done in the US reported
that 11% of MSM used Viagra in the 12
months preceding the interview [26].
Only a proportion of these medications
are used for erectile dysfunction; recrea-
tional use of these drugs to improve
sexual performance is also common.
The annual revenues generated by sales
of Viagra and Cialis were respectively
over $1 billion and $747 million in 2005
[27,28]. Pharmaceutical companies even
have been accused of inventing new
diseases, such as sexual dysfunction in
women, in order to create new drug
markets [29,30]. Other drugs that are
widely used to improve libido or sexual
pleasure are often unapproved indica-
tions of approved drugs (e.g., testosterone
and amyl nitrate or ‘‘poppers’’) or re-
stricted (i.e., illegal) drugs (e.g., crystal
methamphetamine) [26,31].
This demonstrates a clear discrepancy
between the widespread medicalisation of
sexual behaviour and the lack of research
in this ﬁeld. A systematic search of 9,979
abstracts of the 2006 international AIDS
conference in Toronto using the keyword
‘‘libido’’ resulted in four abstracts, while
searching for the term ‘‘sexual dysfunc-
tion’’ resulted in one abstract. However, a
search for the keyword ‘‘resistance’’ pro-
duced 486 abstracts.
We believe that sexual dysfunction
needs more attention from researchers
developing clinical trials, since it seems to
be quite important from the patients’
perspective. Focus group discussions
among PLHA performed in Europe have
shown that sexual well-being in general
was felt to be a crucial part of overall
HRQOL, and that sexual dysfunction was
perceived to decrease it signiﬁcantly [32].
PLHA are confronted with many factors
that may interfere with their sexual well-
being: the psychological impact of the
HIV infection itself, the stigma associated
with the infection, hormonal abnormal-
ities, fear of transmitting the infection to
others, depression, illnesses, and the side
effects of drugs such as antiretrovirals.
With respect to the latter, PLHA often
attribute sexual problems speciﬁcally to
prescribed drugs which they are taking,
and this may ultimately compromise both
adherence and secondary prevention. In
one study in Italy, sexual dysfunction was
associated with poorer adherence to
protease inhibitor–containing antiretro-
viral treatment regimens [33].
Moreover, many drugs have been
shown to potentially interfere with sexual
functioning (e.g., anti-hypertensive med-
ication, anti-depressive medication, etc.)
[34]; thus sexual health questions should
be included in all QOL questionnaires
during trials with new drugs.
Conclusion
Sexual health is an important contribu-
ting factor to overall quality of life;
therefore we propose that speciﬁc ques-
Figure 1. Medications for Sexual Dysfunction
Available in One Private Pharmacy in Antwerp,
Belgium (Photo: O. Koole)
doi:10.1371/journal.pctr.0020008.g001
Box 1. Questions on Sexual Health
in WHOQOL-HIV Questionnaire
1. How well are your sexual needs fulfilled?
2. Are you bothered by any difficulties in your
sex life?
3. How satisfied are you with your sex life?
4. How would you rate your sex life?
5. How important to you is your sexual life?
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tions regarding sexual health, including
sexual functioning, should be included in
quality of life questionnaires in HIV
clinical trials.
Moreover, a speciﬁc validated question-
naire needs to be developed for studying
HIV-related sexual health problems, not
only for use in industrialised countries but
also in countries with limited resources.
Obviously, besides the importance of
posing sexual health questions in HRQOL
questionnaires, asking patients about
their sexual health during consultations
remains essential. While discussing such
topics in the context of safer sex practices
may increase the quality of life for
individual patients, from a public health
point of view it can be viewed as con-
tributing to primary HIV prevention. &
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